TriLipix Exceeding Abbott’s Expectations Shortly After Launch, Execs Say
Executive Summary
Shortly after the launch of TriLipix, Abbott is seeing patients switch from its established fenofibrate TriCor to the next-generation drug- a welcoming sign for the firm, given that TriCor is expected to face generics in 2011
You may also be interested in...
With Strong Humira Sales Growth, Abbott Is Bullish On Its Second-Quarter Results
The drug maker also reports rising sales for its dyslipidemia franchise.
AstraZeneca To Co-Promote Abbott’s TriLipix; NDA Is Filed For Crestor/TriLipix
AstraZeneca and Abbott announce co-promotion agreement for TriLipix ahead of an FDA decision on a jointly-developed investigational Crestor/TriLipix compound.
American College Of Cardiology Meeting, In Brief
Statin "reloading" may help angioplasty patients avoid heart attack: The pleiotropic effects of statins extend to the PCI lab, where they show benefits for patients dosed before angioplasty, according to evidence presented during the American College of Cardiology scientific sessions in Orlando, Fla., March 29-31. In the ARMYDA-RECAPTURE trial, patients with stable angina or non-ST-elevation acute coronary syndrome chronically treated with statins were "reloaded" with 80 mg of atorvastatin (Pfizer's Lipitor) 12 hours before percutaneous coronary intervention and given another 40 mg before the procedure. They had a significant 48 percent reduction in relative risk of a major adverse cardiac event 30 days after angioplasty. The large majority of patients undergoing PCI already take statins, but the beneficial effect may wane, said principal investigator Germano Di Sciascio. A new loading dose of atorvastatin "recaptures" that effect